Related Experiment Video
Updated: Jul 25, 2025

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
[Optimization of secondary prevention in patients with high-risk atherothrombotic ischemic stroke or transient
A A Kulesh1, S N Yanishevskiy2, D A Demin3
1Vagner Perm State Medical University, Perm, Russia.
Insights
Intensified secondary prevention strategies, including dual antiplatelet or antithrombotic therapy and aggressive lipid lowering, significantly reduce recurrent stroke and death risk in high-risk atherothrombotic ischemic stroke (ATIS) patients.
Area of Science:
- Cardiology
- Neurology
- Vascular Medicine
Context:
- Atherothrombotic ischemic stroke (ATIS) encompasses patients with severe extracranial, intracranial atherosclerosis, or aortic arch atheromatosis.
- Effective secondary prevention is crucial for mitigating major vascular events and mortality in these high-risk individuals.
Purpose:
- To outline optimal medical strategies for short- and long-term secondary prevention of ATIS.
- To discuss evidence-based approaches for reducing recurrent stroke and death based on recent research and guidelines.
Summary:
- Recent studies support individualized and intensified secondary prevention for ATIS.
- Recommended interventions include short-term dual antiplatelet therapy (ASA with clopidogrel/ticagrelor).
- Long-term dual antithrombotic therapy (ASA with low-dose rivaroxaban) and intensive lipid-lowering (statin combinations or PCSK9 inhibitors) are advised.
Impact:
- These intensified strategies can significantly reduce the risk of recurrent stroke and death in high-risk ATIS patients.
- Personalized treatment plans enhance patient outcomes and reduce healthcare burden.
Abstract:
High and very high risk atherothrombotic ischemic stroke (ATIS) includes patients with severe extracranial atherosclerosis, any intracranial atherosclerosis, and aortic arch atheromatosis. The article discusses the most effective approaches to medical short- and long-term secondary prevention of ATIS, major vascular events and death, based on the results of modern research and current clinical guidelines. Clinical studies of recent years have proven the possibility of individualization and intensification of secondary prevention of ATIS. In the treatment of high-risk patients, it is advisable to use more widely short-term dual antiplatelet therapy (combination of ASA with clopidogrel or ticagrelor), long-term dual antithrombotic therapy (combination of ASA and rivaroxaban at a dose of 2.5 mg twice a day not earlier than 30 days from the development of stroke or TIA) to reduce the risk of recurrent stroke and death, as well as intensive lipid-lowering therapy (including the use of a combination of statins and ezetimibe or PCSK9 inhibitors).
Related Concept Videos
Atherosclerosis IV: Nursing Management
Atherosclerosis III: Management
Venous Thrombosis III: Interprofessional Care
Acute Coronary Syndrome IV: Interprofessional Care
Peripheral Artery Disease III: Interprofessional Care
Coronary Artery Disease IV: Preventive Measures

